GM1 Gangliosidosis Gene Therapy Study
Contact
Description
The purpose of this study is to test and find a safe dose of this investigational gene therapy PBGM01 (also known as, the study drug) in children who have been diagnosed with the early infantile or late infantile form of GM1. The study will also try to determine how PBGM01 might affect the GM1 disease course over time. The study drug is investigational, which means it has not been approved for marketing by the FDA. This study is the first time PBGM01 will be given to humans, so we do not know for sure if participants will benefit from this study.
Eligibility and criteria
IRB Number:
20-017647
Eligible age range:
Clinical trial phase:
Phase I
Phase II
Official title:
What to expect
- Receiving the investigational study drug (PBGM01) one time via an injection into the space just below the brain (intracisternal injection).
- Taking oral steroids for approximately two months.
- Undergoing a series of research blood and urine tests, physical and neurological exams, cognitive and behavioral assessments, lumbar punctures (LP), ultrasounds, hearing and vision tests, nerve conduction studies, spinal x-rays, and MRIs.
- Having some of these study procedures performed under general anesthesia.
Related specialties

We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.